Investigational drug · Phase 2
SCTT11
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for TED.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SCTT11"
First trial start
2025
Feb 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCTT11", any sponsor or status.
Conditions studied
As listed on its trial records.
- TED
Largest trials
Live from ClinicalTrials.gov: studies naming "SCTT11" as an intervention, largest first.
- A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.Pivotal-lookingNot yet recruiting
Sinocelltech Ltd.Industry
NCT06769984 · 100 participants (planned) · Start Feb 19, 2025 · Primary completion Jun 24, 2026
Drug: SCTT11; Placebo · For: TED
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.